Skip to main content
SpringerLink
Log in

Kombination von Avelumab und stereotaktischer ablativer Bestrahlung beim metastasierten kastrationsresistenten Prostatakarzinom

Effektivität und Sicherheit – Phase II ICE-PAC

Combining avelumab and stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer

Efficacy and safety—phase II ICE-PAC

  • Journal Club
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ et al (2020) Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 38(5):395–405

    Article  CAS  Google Scholar 

  2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD‑1 antibody in cancer. N Engl J Med 366(26):2443–2454

    Article  CAS  Google Scholar 

  3. Fakhrejahani F, Madan RA, Dahut WL, Karzai F, Cordes LM, Schlom J (2017) Avelumab in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. https://doi.org/10.1200/JCO.2017.35.6_suppl.159

    Article  Google Scholar 

  4. Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD et al (2020) Nivolumab plus Ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkmate 650 trial. Cancer Cell 38(4):489–499.e3

    Article  CAS  Google Scholar 

  5. Kolinsky MP, Gravis G, Mourey L, Piulats JM, Sridhar SS, Romano E et al (2020) KEYNOTE-365 cohort B updated results: pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. https://doi.org/10.1200/JCO.2020.38.6_suppl.103

    Article  Google Scholar 

  6. Berghen C, Joniau S, Ost P, Poels K, Everaerts W, Decaestecker K et al (2021) Progression-directed therapy for oligoprogression in castration-refractory prostate cancer. Eur Urol Oncol 4(2):305–309

    Article  Google Scholar 

  7. Deek MP, Taparra K, Phillips R, Velho PI, Gao RW, Deville C et al (2021) Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer. Eur Urol Oncol 4(3):447–455

    Article  Google Scholar 

  8. Deek MP, Yu C, Phillips R, Song DY, Deville C, Greco S et al (2019) Radiation therapy in the definitive management of oligometastatic prostate cancer: the Johns Hopkins experience. Int J Radiat Oncol Biol Phys 105(5):948–956

    Article  Google Scholar 

  9. Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES et al (2019) Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World J Urol 37(12):2623–2629

    Article  Google Scholar 

  10. Triggiani L, Mazzola R, Magrini SM, Ingrosso G, Borghetti P, Trippa F et al (2019) Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol 37(12):2631–2637

    Article  CAS  Google Scholar 

  11. Yoshida S, Takahara T, Arita Y, Ishii C, Uchida Y, Nakagawa K et al (2019) Progressive site-directed therapy for castration-resistant prostate cancer: localization of the progressive site as a prognostic factor. Int J Radiat Oncol Biol Phys 105(2):376–381

    Article  Google Scholar 

  12. Lohaus F, Zöphel K, Löck S, Wirth M, Kotzerke J, Krause M et al (2019) Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease? Eur Urol 75(4):548–551

    Article  Google Scholar 

  13. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700–712

    Article  CAS  Google Scholar 

  14. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM et al (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA‑4 blockade. Cancer Res 60(9):2444–2448

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Kinderurologie und Uroonkologie, Universitätsklinik Essen, Westdeutsches Tumorzentrum, Essen, Deutschland

    Ulrich Alexander Krafft FEBU

Authors
  1. Ulrich Alexander Krafft FEBU
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Alexander Krafft FEBU.

Ethics declarations

Interessenkonflikt

U. A. Krafft gibt an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krafft, U.A. Kombination von Avelumab und stereotaktischer ablativer Bestrahlung beim metastasierten kastrationsresistenten Prostatakarzinom. Urologe 61, 301–303 (2022). https://doi.org/10.1007/s00120-021-01743-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-021-01743-x

Search

Navigation